Hans C Lee
Overview
Explore the profile of Hans C Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
1852
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muchtar E, Dispenzieri A, Sanchorawala V, Hassan H, Mwangi R, Maurer M, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 39994333
Autologous stem cell Transplant (ASCT)-related mortality (TRM) in AL amyloidosis remains elevated. AL amyloidosis patients (n = 1718) from 9 centers, transplanted 2003-2020 were included. Pre-ASCT variables of interest were...
2.
Qin L, Moreno Rueda L, Ray U, Mahmud I, Tan L, Lorenzi P, et al.
Blood
. 2025 Feb;
PMID: 39912779
Plasma cell dyscrasias encompass a spectrum from the precursors monoclonal gammopathy of undetermined significance and smoldering myeloma to symptomatic myeloma, but the genes that enable progression and confer poor prognosis...
3.
Moreno Rueda L, Wang H, Akagi K, Dang M, Vora A, Qin L, et al.
Cell Rep Med
. 2025 Jan;
6(2):101925.
PMID: 39855192
Multiple myeloma is a clonal plasma cell (PC) dyscrasia that arises from precursors and has been studied utilizing approaches focused on CD138 cells. By combining single-cell RNA sequencing (scRNA-seq) with...
4.
Ramasamy K, Vij R, Kuter D, Cella D, Durie B, Abonour R, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Jan;
PMID: 39799046
Background: This analysis explored real-world characteristics, treatment patterns and clinical outcomes in patients with relapsed or refractory multiple myeloma (RRMM) previously treated with lenalidomide and an anti-CD38 monoclonal antibody (mAb)...
5.
Pasvolsky O, Marcoux C, Wang Z, Milton D, Pal B, Tanner M, et al.
Transplant Cell Ther
. 2025 Jan;
31(3):166.e1-166.e9.
PMID: 39746546
Patients with multiple myeloma (MM) without high-risk cytogenetic abnormalities are classified as having standard-risk MM (SRMM), and data focusing on their outcomes after autologous hematopoietic stem cell transplantation (autoHCT) are...
6.
Manzar G, Dudzinski S, Yoder A, Seo A, Nasr L, Rafei H, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Dec;
PMID: 39709251
Background: The prognosis of multiple myeloma involving the central nervous system (CNS-MM) is poor. We report outcomes of CNS-MM treated with CNS-directed radiation therapy (RT). Methods: We retrospectively reviewed patients...
7.
Marcoux C, Pasyar S, Milton D, Khan H, Tanner M, Bashir Q, et al.
Br J Haematol
. 2024 Nov;
206(2):763-765.
PMID: 39610225
No abstract available.
8.
Terebelo H, Omel J, Wagner L, Hardin J, Rifkin R, Ailawadhi S, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
25(1):58-66.
PMID: 39603959
Background: Over the last 15 years, improvements in patient management and treatments have been associated with longer survival in patients with multiple myeloma (MM). The Connect MM Registry is a...
9.
Ailawadhi S, Lee H, Omel J, Toomey K, Hardin J, Gasparetto C, et al.
Blood Cancer J
. 2024 Nov;
14(1):198.
PMID: 39528478
Limited data exist on the effects of induction treatment in patients with newly diagnosed multiple myeloma (NDMM) and renal impairment (RI), who may also be ineligible for autologous stem cell...
10.
Pasvolsky O, Marcoux C, Milton D, Pal B, Tanner M, Bashir Q, et al.
Blood Cancer J
. 2024 Nov;
14(1):189.
PMID: 39482325
Autologous transplantation remains the standard of care for eligible multiple myeloma (MM) patients, yet optimal CD34 cell dose remains unclear. We conducted a retrospective study on MM patients undergoing upfront...